Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia. The gene discussed is EIF4E; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.